SG
ELDN icon

Sankala Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Sankala Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.14K Buy
+1,425
New +$5.18K ﹤0.01% 461

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Sankala Group's ELDN Position: Q2 2026 in Review

Sankala Group opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 1,425 shares worth $5.14K. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings.

160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Sankala Group held 1,425 shares of Eledon Pharmaceuticals worth $5.14K as of Q2 2026.
  • Eledon Pharmaceuticals was a new Sankala Group position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #461 holding.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.